Fresenius Medical Care North America ("FMCNA"), the North
American division of
Fresenius Medical Care
(
FMS
), recently revealed that it is recognizing over 25 patients in the
U.S. who will turn 100 years or more in age in 2012. These
individuals are carrying on with active, wholesome lives even
though they lack proper kidney function.
Dialysis is a life-sustaining mechanism that purifies waste
products from the blood stream and regulates the chemistry of the
body when an individual is struck with kidney failure. Dialysis
patients invariably need this ongoing therapy until they are
recipients of kidney transplant.
Thanks to dialysis treatment, victims of kidney failure are now
bestowed with a higher probability of leading high quality life
style for several years. The company stated that important
attributes for faring well on dialysis include commitment to the
planned treatment and adjustment of lifestyle, particularly
exercise and dietary matters.
Some of the centenarian patients of FMCNA have been on dialysis
for several years. Each year, FMCNA identifies about 350
individuals with its Quarter Century Patient Recognition Program,
which felicitates individuals who have undergone treatment for a
quarter century or longer.
One factor that prolongs longevity of kidney patients is the
wide array of available treatment options. FMCNA is determined to
provide a wide range of services to its beneficiaries.
In addition, FMCNA provides educational programs at no extra
cost via its Treatment Options Program. These programs are intended
to educate victims about different treatment options and urges them
to find the treatment that most benefits them.
Dialysis patients can now avail of noteworthy technical progress
in the field of dialysis treatment. FMCNA has over 30 years of
expertise in dialysis treatment and its technology is capable of
both purifying blood and facilitating a balanced life for patients
on dialysis.
A large proportion of dialysis patients attribute their
longevity to maintaining treatment, exercising periodically and
eating wholesome food, besides pursuing a busy life style. Dialysis
patients who both recognize their condition and are committed to
their treatment regimen are expected to harvest optimal results
from dialysis.
Fresenius is the largest provider of dialysis products and
services on the planet. The company operates a network of about
2,874 dialysis clinics across North America and overseas markets to
provide dialysis treatment to approximately 228,239 patients, as of
September 30, 2011. Fresenius' principal competitor in the U.S. is
DaVita Inc.
(
DVA
), which also provides dialysis services to patients suffering from
chronic kidney failure or ESRD.
DAVITA INC (
DVA
): Free Stock Analysis Report
FRESENIUS MED (
FMS
): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment
Research